Treatment With MK0966 for the Prevention of Prostate Cancer (0966-201)
NCT00060476 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 15000
Last updated 2017-05-09
Summary
To determine the efficacy and safety of an investigational compound (MK0966) for the prevention of prostate cancer.
Conditions
Interventions
- DRUG
-
rofecoxib
- DRUG
-
Comparator: placebo (unspecified)
Sponsors & Collaborators
- lead INDUSTRY
Principal Investigators
-
Medical Monitor · Merck Sharp & Dohme LLC
Study Design
- Allocation
- RANDOMIZED
- Purpose
- PREVENTION
- Masking
- DOUBLE
- Model
- PARALLEL
Eligibility
- Min Age
- 50 Years
- Max Age
- 75 Years
- Sex
- MALE
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2003-01-08
- Primary Completion
- 2004-12-08
- Completion
- 2004-12-08
More Related Trials
-
Study of RV001V in Biochemical Failure Following Curatively Intended Therapy For Localized Prostate Cancer
NCT04114825 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2
-
A Study Evaluating the Safety, Pharmacokinetics, and Activity of RO7656594 In Participants With Advanced or Metastatic Prostate Cancer
NCT05800665 ·Status: RECRUITING ·Phase: PHASE1
-
A Study to Assess BMS-986460 in Participants With Metastatic Castration-resistant Prostate Cancer
NCT06067841 ·Status: RECRUITING ·Phase: PHASE1
-
Dose-Seeking Trial of PCK3145 in Asymptomatic, Castrate Metastatic Prostate Cancer Patients.
NCT00695851 ·Status: COMPLETED ·Phase: PHASE1
-
Celecoxib (Celebrex) Versus Placebo in Men With Recurrent Prostate Cancer
NCT00136487 ·Status: COMPLETED ·Phase: PHASE2/PHASE3
-
Valproic Acid in Treating Patients With Progressive, Non-Metastatic Prostate Cancer
NCT00670046 ·Status: TERMINATED ·Phase: PHASE2
-
A Phase II Study of BAY 43-9006 (Sorafenib) in Metastatic, Androgen-Independent Prostate Cancer
NCT00090545 ·Status: COMPLETED ·Phase: PHASE2
-
A Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Antitumor Activity of INV-9956 in Adult Patients With Advanced Metastatic Castration Resistant Prostate Cancer
NCT06609005 ·Status: RECRUITING ·Phase: PHASE1/PHASE2
-
Sorafenib in Treating Patients With Metastatic or Recurrent Prostate Cancer
NCT00093457 ·Status: COMPLETED ·Phase: PHASE2
-
Mifepristone (RU-486) in Androgen Independent Prostate Cancer
NCT00140478 ·Status: COMPLETED ·Phase: PHASE2
-
PROSTVAC in Combination With Nivolumab in Men With Prostate Cancer
NCT02933255 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
Trial of Neoadjuvant Enoblituzumab vs SOC in Men With High-Risk Localized Prostate Cancer
NCT06014255 ·Status: RECRUITING ·Phase: PHASE2
-
Phase Ia/Ib Talazoparib + Tazemetostat for mCRPC
NCT04846478 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE1
-
A Phase II Trial of TPI 287 in Patients With Metastatic Prostate Cancer
NCT00479635 ·Status: TERMINATED ·Phase: PHASE2
-
Fractionated and Multiple Dose 225Ac-J591 for Progressive mCRPC
NCT04506567 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE1/PHASE2
-
Study of Pembrolizumab (MK-3475) in Participants With Metastatic Castration-Resistant Prostate Cancer (mCRPC)(MK-3475-199/KEYNOTE-199)
NCT02787005 ·Status: COMPLETED ·Phase: PHASE2
-
Sorafenib in Hormone Naïve Biochemical Recurrence of Prostate Cancer
NCT00694291 ·Status: WITHDRAWN ·Phase: PHASE2
-
Eflornithine in Treating Patients At High Risk of Developing Prostate Cancer
NCT00006101 ·Status: COMPLETED ·Phase: PHASE2
-
Study Using CP-461 to Treat Advanced Prostate Cancer
NCT00036075 ·Status: COMPLETED ·Phase: PHASE2
-
Trial of RNActive®-Derived Prostate Cancer Vaccine in Metastatic Castrate-refractory Prostate Cancer
NCT01817738 ·Status: TERMINATED ·Phase: PHASE1/PHASE2
-
Safety and Anti-Tumor Study of Oral EPI-506 for Patients With Metastatic Castration-Resistant Prostate Cancer
NCT02606123 ·Status: TERMINATED ·Phase: PHASE1/PHASE2
-
The Specific Role of Isoflavones in Reducing Prostate Cancer Risk
NCT00617617 ·Status: COMPLETED ·Phase: PHASE2
-
A Study of ARV-766 Given by Mouth in Men With Metastatic Prostate Cancer
NCT05067140 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE1/PHASE2
-
Perifosine in Treating Patients With Metastatic, Androgen-Independent Prostate Cancer
NCT00060437 ·Status: COMPLETED ·Phase: PHASE2
-
Rosiglitazone (Avandia) vs. Placebo for Androgen Dependent Prostate Cancer
NCT00182052 ·Status: COMPLETED ·Phase: PHASE3